HHS Chief Faces Call To Fire FDA Brass After Biogen Approval
A nonprofit consumer advocate wants U.S. Food and Drug Administration decision makers behind the controversial approval of the first Alzheimer's treatment in nearly two decades to leave their positions....To view the full article, register now.
Already a subscriber? Click here to view full article